HIGHLIGHTS
SUMMARY
The authors systematically assessed and updated the results about the efficacy and effectiveness of COVID-19 vaccines to prevent the infection of Delta and Omicron variants based on phase III randomized clinical trials (RCTs) and observational studies. Breakthrough infection was selected among vaccinated subjects frontiersin.org 10.3389/fimmu.2022.945930 COVID-19 vaccines BNT162b2 and NVX-CoV2373; ≥14 days for COVID-19 vaccines BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, CoronaVac, BBV152, CVnCoV, WIV04, Sputnik V, HB02, and SCB-2019; or after the single-dose vaccination for COVID-19 vaccines Ad26.COV2.S; and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.